Quetiapine Augmentation in Severe Obsessive Compulsive Disorder

Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00254735

Enrollment

Registered

2005-11-17

Start date

2002-04-30

Completion date

2006-03-31

Last updated

2007-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder

Keywords

Obsessive Compulsive Disorder (OCD)

Brief summary

The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.

Interventions

DRUGquetiapine fumarate

DRUGSSRI/Clomipramine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine

Exclusion criteria

* Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intolerance or lack of response to quetiapine, use of antihypertensive medication with changing doses

Design outcomes

Primary

Measure	Time frame
Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.	—

Secondary

Measure	Time frame
Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.	—
Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026